يعرض 1 - 20 نتائج من 30,744 نتيجة بحث عن '(( 3 mm decrease ) OR ((( _ largest decrease ) OR ( _ ((a decrease) OR (small decrease)) ))))', وقت الاستعلام: 0.70s تنقيح النتائج
  1. 1
  2. 2
  3. 3
  4. 4

    Supplementary Material for: Longitudinal Decrease in Left Ventricular Size with Age: Impact on Mortality and Cardiovascular Hospitalization حسب figshare admin karger (2628495)

    منشور في 2025
    "…Participants were categorized by LVEDD change from baseline: No Change (<5 mm), Decreased (≥5 mm), and Increased (≥5 mm). Results: A decrease in LVEDD was observed in 24% of participants (mean change -9±3 mm) and was significantly associated with older age, female sex, decreased volumes, concentric remodeling and diastolic dysfunction. …"
  5. 5
  6. 6
  7. 7

    (A) Digital designing of premolar to decrease 1 mm of root surface, (B) 3D printed tooth compared to artificial tooth of model. حسب Samar S. Alaghbari (21863491)

    منشور في 2025
    "…<p>(A) Digital designing of premolar to decrease 1 mm of root surface, (B) 3D printed tooth compared to artificial tooth of model.…"
  8. 8
  9. 9

    Why does task performance decrease with burst length? حسب Swathi Anil (17382903)

    منشور في 2025
    "…See <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1013125#pcbi.1013125.s001" target="_blank">S1 Appendix</a>.…"
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx حسب Asmae El Maangar (19690522)

    منشور في 2025
    "…We show that using hydrotropes as a diluent decreases the viscosity of solutions by more than a factor of ten, even under high load by extracted cations. …"
  17. 17
  18. 18

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc حسب Lei Wang (6656)

    منشور في 2025
    "…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …"
  19. 19
  20. 20